Congenital chylothorax

Congenital chylothorax is a rare condition present at birth in which chyle (lymphatic fluid rich in fats and proteins) accumulates in the pleural space surrounding the lungs. It is the most common cause of pleural effusion in neonates and fetuses. The condition results from malformation or dysfunction of the thoracic duct or lymphatic system, leading to leakage of chyle into the chest cavity. When detected prenatally, it may present as fetal hydrops (abnormal fluid accumulation in multiple body compartments). After birth, affected neonates typically present with respiratory distress, tachypnea (rapid breathing), and decreased breath sounds on the affected side. The effusion may be unilateral or bilateral and can cause significant compression of the developing lungs, potentially leading to pulmonary hypoplasia if present during fetal development. Congenital chylothorax primarily affects the respiratory and lymphatic systems. Key clinical features include progressive respiratory compromise, nutritional deficiencies due to loss of proteins, immunoglobulins, and lymphocytes in the chyle, and electrolyte imbalances. Affected infants may develop immunodeficiency due to ongoing lymphocyte loss, increasing susceptibility to infections. In some cases, the condition is associated with chromosomal abnormalities (such as Turner syndrome or Down syndrome), Noonan syndrome, or other lymphatic malformation syndromes. Treatment typically begins with conservative management, including thoracentesis (drainage of the pleural fluid) or chest tube placement to relieve respiratory distress, along with dietary modifications such as medium-chain triglyceride (MCT)-enriched formula or total parenteral nutrition to reduce chyle production. Octreotide, a somatostatin analogue, may be used to decrease lymphatic flow. If conservative measures fail after several weeks, surgical intervention such as thoracic duct ligation or pleurodesis may be considered. With appropriate management, many infants recover fully, though outcomes depend on the severity of the effusion, the presence of associated anomalies, and the degree of pulmonary hypoplasia.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Congenital chylothorax